Navigation Links
Valeant to Acquire Polish Products
Date:10/30/2009

ALISO VIEJO, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced that it has agreed to acquire the rights to several prescription and cosmetic dermatology products from a privately-held, Polish specialty pharmaceutical company. The products have approximately $8 million in annual sales and Valeant will acquire the rights to all products for approximately $18 million. A portion of the purchase price was paid upon signing and the remaining balance will be paid upon closing. The transaction is expected to close in the first quarter of 2010 and will be accretive to Valeant in 2010.

"We continue to focus our development efforts in building leading dermatology franchises in each of our select regions," stated J. Michael Pearson, chairman and chief executive officer. "This latest transaction adds new complementary prescription and cosmetic products to our current portfolio in Central Europe and fits in well with our existing infrastructure. In addition, the dermatology products will increase our visibility with the dermatologists in these markets."

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements, including, but not limited to, statements regarding the consummation of the acquisition, the potential for Valeant to build its regional franchises and the impact of the acquisition on Valeant's results of operation. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the U.S. Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)

    Contact:
    Laurie W. Little
    Valeant Pharmaceuticals
    949-461-6002
    laurie.little@valeant.com

SOURCE Valeant Pharmaceuticals International


'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou
2. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
3. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
4. BioMarin Acquires Huxley Pharmaceuticals, Inc.
5. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
6. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
7. BD Announces Agreement to Acquire HandyLab, Inc.
8. Seguro Acquires Worldwide Rights to Johns Hopkins Abdominal Surgery Device
9. Somanetics Acquires Exclusive Sublicense to Cerebral Autoregulation Monitoring Technology Developed at The Johns Hopkins University
10. Onyx Pharmaceuticals to Acquire Proteolix, Inc.
11. ResMed Acquires Laboratoires Narval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... SAN DIEGO and PALMA, ... Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical ... announced that the first patient has been enrolled ... of lead candidate, SNF472, for the treatment of ... haemodialysis (HD). Most ESRD patients, in ...
(Date:1/21/2017)... 20, 2017 Research and Markets has ... Market By Type of Test (Tumor, Clinical Chemistry, Microbiology, Esoteric), ... of Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS etc.), Forecast to 2022" ... ... healthcare services, market segments, especially clinical lab testing, which has ...
(Date:1/21/2017)... Jan 20, 2017 Research and Markets has ... & Trends - Technology, Route Of Administration, End User - Forecast ... ... poised to grow at a CAGR of around 7.8% over the ... This industry report analyzes the global markets for Advanced Drug ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... ... Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education and Research (FAER), ... (AAOS) and the Cigna Foundation, encourages proposals supporting high quality research using ...
(Date:1/23/2017)... ... 2017 , ... “The Inn at the Mill”: a story of love and redemption, hope ... become happy and content. , “The Inn at the Mill” is the creation of ... and Vermont and is now living in Berks County on Crow Hill. The ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... launched online education programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist ... a seafood-rich diet. These resources have been developed for use by nutrition ...
(Date:1/23/2017)... ... ... Infallible Characteristics of Christ”: a fascinating and entrancing novel exploring the gifts and ... author, Rev. Dr. Robert W. Thomas, the third of seven siblings. He was a ... pastor for over fifteen years. He is a graduate of N.C. College of Theology ...
(Date:1/22/2017)... MALO, FRANCE (PRWEB) , ... January 22, 2017 , ... ... Indian Ocean, isolated from the rest of the world with ZANZIBAR MILKY CREAM. Inspired ... Phytocéane used key ingredients like Virgin Coconut Oil and moisturizing vegetal coral to create ...
Breaking Medicine News(10 mins):